GrowBLOX Granted Occupancy Permit for Las Vegas Cannabis Cultivation Facility

Monday, May 23, 2016 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LAS VEGAS, May 23, 2016 /PRNewswire/ -- GrowBLOX Sciences, Inc., (OTCQB: GBLX) announced today that it was granted an occupancy

permit for its 28,000 sf. Cannabis cultivation facility at 3550 West Teco Ave in Las Vegas, Clark County, Nevada.

"This is a great step toward final inspection and moving into

the revenue stage," said John Poss, GrowBLOX CEO and CFO.

The Teco cannabis cultivation facility will be initially equipped with 200 grow lights supporting approximately 800 marijuana plants, with an initial production of 112 pounds of marijuana per month and serve the patient population of Nevada.  When fully developed, 1,000 grow lights and 4,000 plants are expected to generate over $20 million in revenues per year from the facility.

"We aim to reach 4,000 cannabis plants as soon as possible, certainly within six to nine months," Poss said.

"Our occupancy license allows us to move forward in a new, cash flow generating phase for GrowBLOX.  This development provides excitement for me and our teams and the company's prospects," Poss added.

Leslie Bockskor, GrowBLOX Board Member and Founder of Electrum Partners states, "I am encouraged by the best in breed practices and decisions that are going into the cultivation set up and development efforts led by John Poss and his team."

The Teco cultivation facility will provide the platform for our continued research and the development of new products, technology and modalities for cannabis cultivation and production.

About GrowBLOX Sciences, Inc.GrowBLOX Sciences, Inc. (GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The Company has leading technology and cannabis industry processes, with a "big" data-driven clinical research and development loop to bring relief to patients in communities across the country. Through our GBS PR subsidiary, we are developing and globally distributing our GrowBLOX â„¢ suite of cultivation and growing chambers. To learn more about GrowBLOX Sciences, Inc., go to: 

Forward-Looking StatementsThis press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

GrowBLOX is a registered trademark of GrowBLOX Sciences, Inc.

Contact InformationCorporate:GrowBLOX Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118 866-721-0297, or  Liz Bianco Publicity Director,, Investors: John Poss,

To view the original version on PR Newswire, visit:

SOURCE GrowBLOX Sciences, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store